mHSPC VL

Which Patients with mHSPC Can Be Offered a Treatment Break (De-Escalation Strategies) and How to Manage the Break? "Presentation" - Bertrand Tombal

Details
At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Bertrand Tombal examines treatment de-escalation strategies in metastatic hormone-naive prostate cancer. He explores three main approaches: stopping ADT while continuing ARPI, stopping ARPI while maintaining ADT, and revisiting intermittent androgen deprivation therapy, and emphasizes the importance of clinical trials like the P6 p...

Escalation Strategies in Patients with mHSPC and an Unfavourable PSA Decline – Is More Better? "Presentation" - Mary-Ellen Taplin

Details
At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Mary-Ellen Taplin discusses the significance of PSA nadir values in metastatic hormone-sensitive prostate cancer treatment, reviewing data from SWOG 9346 and CHAARTED trials that establish PSA nadir as a prognostic indicator while emphasizing that unfavorable PSA decline doesn't necessarily indicate progression. Biographies: Mary-E...

How to Manage Patients with Low-Volume on Conventional and High-Volume on NGI "Presentation" - Dana Rathkopf

Details
At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Dana Rathkopf addresses the complex challenge of managing prostate cancer patients who show low-volume disease on conventional imaging but high-volume disease on next-generation PET imaging. The presentation explores evidence suggesting PET-only metastases may be more indolent than conventional imaging-visible disease. Biographies:...

Management of Patients with mHSPC and Early Progression on Combination Therapy "Presentation" - Christopher Sweeney

Details
At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Christopher Sweeney discusses strategies for managing early progression after combination therapy in prostate cancer. He emphasizes the importance of proper patient and tumor profiling while presenting ENZAMET trial data showing survival differences based on progression patterns. Biographies: Christopher Sweeney, MBBS, Professor of...

Management of Frail Patients with mHSPC "Presentation" - Maria De Santis

Details
At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Maria De Santis presents an overview of managing frail patients with metastatic hormone-sensitive prostate cancer. The presentation explores treatment efficacy data and challenges in frail patients, while emphasizing the importance of supportive interventions and individualized treatment approaches. Biographies: Maria De Santis, MD...

Future Changes in the Setting of mHSPC "Presentation" - Gerhardt Attard

Details
At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Gerhardt Attard discusses the future landscape of prostate cancer treatments and biomarkers, introducing STAMPEDE2's multi-arm trial design. Dr. Attard also addresses key challenges in radiographic progression-free survival measurements, patient selection, and treatment sequencing. Biographies: Gerhardt Attard, MD, PhD, FRCP, John...

Importance of Bone Protection in Prostate Cancer Treatment "Presentation" - Noel Clarke

Details
At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Noel Clarke presents findings from the STAMPEDE trial regarding fracture risk and bone protection in prostate cancer patients. The presentation demonstrates that zoledronic acid reduces fracture incidence by about 50% in metastatic disease, and treatment intensification with abiraterone shows substantial fracture risk reduction, wh...

Balancing Risks and Benefits of ADT in Prostate Cancer Treatment "Discussion"

Details
At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), a panel discussion explores key questions surrounding androgen deprivation therapy. The experts debate testosterone replacement safety after ADT and the controversy between GnRH agonists and antagonists in cardiovascular outcomes, emphasizing that patient background and risk factor management may influence results more than drug ch...

Ideal Sequence After ADT Alone or ADT plus ARPI for mHSPC "Presentation" - Ian Davis

Details
At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Ian Davis addresses the complexities of treatment sequencing following doublet therapy for metastatic hormone-sensitive prostate cancer. The presentation explains that treatments like docetaxel, abiraterone, and enzalutamide show greater benefits in hormone-sensitive states than in CRPC, while warning against approaches that might...

Ideal Sequence After ADT plus ARPI plus Docetaxel for mHSPC "Presentation" - Karim Fizazi

Details
At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Karim Fizazi examines treatment sequencing options following triplet therapy in metastatic castration-sensitive prostate cancer. The presentation emphasizes personalizing treatment based on clinical and biological markers while addressing key scenarios of AR mutations, bypass pathways, and lineage plasticity with neuroendocrine dif...